| 摘要 |
<p>The present invention is directed to methods and formulations for reducing, preventing, and/or managing abnormal increases in gastrointestinal motility, and intestinal conditions that cause the same. Methods of using N-2,2,3-tetramethylbicyclo-[2.1.1]heptane-2-amine and formulations comprising N-2,2,3-tetramethylbicyclo-[2.1.1]heptan-2-amine are included.</p> |
